Late-breaking clinical study results

presented at DIGESTIVE DISEASE WEEK (DDW) 2016

 

A new blood test for the detection of Colorectal Cancer (CRC)
Measurement of Natural Killer Cell Activity (NKA) in patients undergoing colonoscopy.

 

CLINICAL STUDY DETAILS

This study was conducted at Maisonneuve-Rosemont Hospital in Montreal, Quebec, Canada by Dr. Gilles Jobin and colleagues. 1047 successive subjects >40 years of age, who underwent colonoscopy, were recruited between October 2014 and January 2016. NK VueTM a novel in vitro diagnostic device (IVDD), was used to measure NKA in these subjects. NKA was compared in subjects with cancer-negative colonoscopies to those with pathologically confirmed CRC.

Preliminary study results will be presented for the first time at DDW 2016, May 21–24, 2016 by Dr. Gilles Jobin, Chief of Gastroenterology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, during the Clinical Science Late-breaking poster session on Tuesday, May 24 starting at 9:30 a.m. in Hall C-SDCC (poster #Tu2088).*

The abstract has been published in the April 2016 supplement of Gastroenterology on page S-1270. Additional study details are available at https://clinicaltrials.gov/ct2/show/NCT02291198. Additional information on NK cells is available by visiting www.atgencanada.com.

 

* ATGen Canada did not provide financial support for this scientific session and did not influence the content in any way.
However, research presented within this scientific session has been supported by ATGen Canada.

 

ABOUT NK VUE

NK Vue is the first commercially available IVDD that measures NKA in a small volume of stimulated whole blood. This IVDD was approved by Health Canada in December 2014 for the following indication: “NK Vue is intended for in vitro diagnostic use, for the monitoring of the immune status of individuals. Measurement of NK cell activity could be a useful tool for assessing changes in immunosurveillance, which, in turn, could be indicative of a condition or disease where NK cell activity has been shown to be affected.”

 

WHO IS ATGen

ATGen is a public immunodiagnostic company focused on the development of in vitro diagnostic devices for the analysis of patients’ immune function. Immunosurveillance performed by lymphoid cells is important in immunity against foreign antigens and tumor cells.

 

Reference:
Jobin, G. et al. Tu2088 A New Blood Test for the Detection of Colorectal Cancer (CRC): Measurement of Natural Killer Cell Activity (NKA) in Patients Undergoing Colonoscopy. Gastroenterology 150, S1270–S1271 (2016).

 

This press release may contain forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release.

 

For Media inquiries please contact Gaétan Huneault, President at 1-855-561-4681, extension 201.